RecruitingNCT04514965

Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)

Measuring Macrophage Activation Markers and Influence on Bile Acid Composition in Patients With Primary Biliary Cholangitis After Treatment With Bezafibrate

Sponsor

University of Aarhus

Enrollment

100 participants

Start Date

Oct 1, 2020

Study Type

OBSERVATIONAL

Conditions

Primary Biliary Cirrhosis

Summary

Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Blood sampling, a medical device called Fibroscan, and others for people with primary biliary cirrhosis. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.